Gestational Diabetes: How Common Is It Worldwide, and Is It Getting Worse?

What the global numbers actually tell you

Gestational diabetes is one of the most common medical complications of pregnancy, and its prevalence has more than tripled in some high-income countries since the 1990s. The International Diabetes Federation's 2021 Diabetes Atlas estimated that 14.0% of live births worldwide are affected by hyperglycaemia in pregnancy, with GDM accounting for the largest share of those cases. That percentage translates to approximately 21.1 million births per year.

These figures are not evenly distributed. A 2022 systematic review and meta-analysis published in The Lancet Diabetes & Endocrinology pooled data from 70 countries and found GDM prevalence ranging from 2.4% in Europe to 27.6% in South-East Asia, depending on diagnostic criteria and population characteristics. The variation is real, not just a measurement artefact.

Why prevalence estimates vary so widely

Two factors drive most of the statistical noise between countries.

First, diagnostic thresholds differ. The World Health Organization recommends diagnosing GDM when a fasting plasma glucose is 5.1 mmol/L (92 mg/dL) or higher on a 75 g oral glucose tolerance test, thresholds set after the landmark HAPO study. The older Carpenter-Coustan criteria used in many US centres set a higher bar. Studies using lower WHO cut-offs will always report higher prevalence.

Second, screening is not universal. Countries without systematic prenatal screening catch fewer cases. This means published prevalence figures in low-income regions almost certainly undercount true burden.

The trajectory is upward everywhere

Using consistent criteria across time points, researchers tracking GDM in the United States found prevalence rose from 6.0% in 2011 to 8.3% in 2019, a relative increase of 38% in under a decade. Similar upward curves have been documented in Australia, the United Kingdom, China, and across Sub-Saharan Africa as urban diets and sedentary work patterns spread.

Regional breakdown: where rates are highest and why

South-East Asia and the Western Pacific

These regions carry the highest absolute burden. India alone accounts for an estimated 2-4 million GDM pregnancies annually. South Asian women have a genetic predisposition to central adiposity and insulin resistance at lower body-mass indices than European-ancestry women, meaning standard BMI cut-offs underestimate metabolic risk. ACOG's 2018 Gestational Diabetes Mellitus practice bulletin explicitly notes that Asian American women may develop GDM at lower weight thresholds, a clinically important difference.

Middle East and North Africa

The Middle East and North Africa region reports some of the highest GDM rates globally, with national estimates in several Gulf states exceeding 20%. High rates of type 2 diabetes in the background population, combined with low physical-activity norms in some cultural contexts, are the main drivers.

Sub-Saharan Africa

Prevalence here was historically reported as low, around 5-6%, but more recent studies using WHO criteria are returning higher figures. A 2020 meta-analysis in BMJ Open found a pooled GDM prevalence of 13.5% across Sub-Saharan Africa when WHO thresholds were applied, nearly double prior estimates. Under-detection in resource-limited settings makes this figure an undercount.

North America and Europe

The United States sits at roughly 8-9% using National Diabetes Data Group criteria and higher with IADPSG/WHO criteria. The CDC reports that GDM affects about 2-10% of US pregnancies depending on the screening method used. Europe shows the lowest rates overall, though countries with large South Asian and Middle Eastern immigrant populations have seen upward trends.

What is driving the global rise?

The GDM epidemic tracks three parallel trends in women's health and reproductive behaviour.

Obesity and metabolic syndrome

Pre-pregnancy overweight and obesity are the single strongest modifiable risk factors for GDM. Each 1-unit increase in pre-pregnancy BMI is associated with a 0.92% increase in GDM risk, and women with a BMI above 30 face roughly three times the risk of women in the normal-weight range. Global female obesity prevalence has more than doubled since 1980, running almost perfectly parallel to the GDM curve.

Delayed childbearing

Women in high-income countries are having first children later. The average age at first birth in the United States crossed 27 years in 2021. Insulin sensitivity declines with age, and each five-year increase in maternal age above 25 confers a roughly 18% higher relative risk of GDM. This effect is biologically distinct from obesity and adds independently to risk.

PCOS: the overlooked multiplier

Polycystic ovary syndrome affects approximately 8-13% of women of reproductive age and is characterised by insulin resistance even in lean women. A 2018 meta-analysis in Human Reproduction found that women with PCOS had a 2.89-fold higher odds of developing GDM compared with women without PCOS, after adjusting for BMI. If you have PCOS and are pregnant or planning pregnancy, your GDM risk is elevated regardless of your weight, and earlier or more intensive glucose monitoring is worth discussing with your clinician.

Diagnostic criteria changes

Part of the apparent global increase reflects a genuine shift in screening standards. After the HAPO study (Hyperglycemia and Adverse Pregnancy Outcomes) was published in 2008, demonstrating a continuous relationship between maternal glucose and adverse outcomes without a clear threshold, the International Association of Diabetes and Pregnancy Study Groups (IADPSG) lowered diagnostic cut-offs in 2010. Countries adopting those criteria immediately reported higher prevalence, not because more women were sick but because more were now correctly identified.

How GDM risk changes across your reproductive life

Understanding your personal GDM trajectory across reproductive life stages helps you anticipate risk, not just react to a diagnosis. Here is how the biology shifts.

Reproductive years (under 35, no prior GDM)

Baseline risk in this group is lowest but not zero. Women with a first-degree relative with type 2 diabetes, a BMI above 25, a history of impaired fasting glucose, or a prior large-for-gestational-age baby should discuss early glucose screening (before 15 weeks in some guidelines) rather than waiting for the standard 24-28 week oral glucose tolerance test. ACOG's practice bulletin recommends risk-factor-based screening at the first prenatal visit for high-risk women.

Trying to conceive with PCOS or insulin resistance

If you are trying to conceive and already managing PCOS or insulin resistance, your pre-conception metabolic state directly shapes GDM risk. Optimising insulin sensitivity before pregnancy, through diet, physical activity, or metformin under clinical guidance, may reduce GDM incidence. The evidence that metformin pre-conception prevents GDM in women with PCOS is suggestive but not definitive; it remains an active area of research.

Advanced maternal age (35 and over)

Women over 35 face compounding risks: age-related insulin resistance, higher pre-pregnancy BMI on average, and greater likelihood of a multiple pregnancy from assisted reproduction. All three raise GDM probability. Some clinicians advocate for early universal screening in women over 35, though guidelines vary. If you are 35 or older and pregnant, ask your provider explicitly about first-trimester glucose testing.

Postpartum and between pregnancies

GDM resolves at delivery by definition. But the metabolic vulnerability does not disappear. Women with a history of GDM have a 10-fold higher lifetime risk of developing type 2 diabetes compared with women who had normoglycaemic pregnancies. The American Diabetes Association recommends a 75 g OGTT at 4-12 weeks postpartum and then ongoing screening every 1-3 years. This step is frequently skipped; attendance rates at postpartum glucose testing hover around 30-50% in most health systems.

Perimenopause

GDM is not a perimenopausal diagnosis because it requires pregnancy. However, a history of GDM is a strong predictor of type 2 diabetes and cardiovascular risk that peaks in the menopausal transition, when oestrogen withdrawal further worsens insulin sensitivity. If you are entering perimenopause and had GDM in any prior pregnancy, annual fasting glucose or HbA1c screening is warranted. Some data suggest that menopausal hormone therapy (MHT) may modestly improve insulin sensitivity, but MHT is not prescribed to prevent diabetes; discuss benefits and risks in your full clinical context.

Ethnic and racial disparities in GDM risk

Race and ethnicity are not biology, but they are proxies for both genetic ancestry and structural determinants of health that shape GDM risk in ways clinical teams need to account for, and that you deserve to understand.

Asian American women face 30-40% higher GDM rates than non-Hispanic white women at equivalent BMI values. Black women in the United States have higher GDM rates than white women and are more likely to experience adverse outcomes from it, a disparity driven by structural barriers to care, differential obesity prevalence, and possibly genetic factors in insulin secretory capacity. Hispanic women, particularly those of Mexican heritage, face elevated rates linked to a high background prevalence of type 2 diabetes in the population.

A 2022 analysis in JAMA found that among US women with GDM, Black and Hispanic women were significantly less likely to receive dietary counselling or insulin initiation within guideline timeframes. These disparities are a failure of the health system, not individual patient behaviour.

Long-term consequences: why prevalence data matter beyond the delivery room

GDM is not a self-contained pregnancy event. Its global rise matters because each affected pregnancy is a window into long-term cardiometabolic risk.

Women with a history of GDM have a nearly sevenfold higher risk of developing type 2 diabetes in later life compared with women who had uncomplicated pregnancies. A 2020 meta-analysis in Diabetologia calculated that the cumulative incidence of type 2 diabetes after GDM reaches approximately 70% at 10-year follow-up in some high-risk populations.

Children born to mothers with GDM face elevated risks of childhood obesity and impaired glucose tolerance, creating an intergenerational cycle that feeds the global prevalence figures of the next generation.

The WHO and ACOG both frame GDM screening as a double opportunity: protecting the index pregnancy and identifying women who need long-term metabolic surveillance.

Current screening standards and how they affect prevalence counts

Global prevalence estimates are only as reliable as the screening tools generating them. Two main approaches exist.

One-step vs. Two-step screening

The United States predominantly uses a two-step approach: a 50 g non-fasting glucose challenge test (GCT) at 24-28 weeks, followed by a 100 g 3-hour OGTT if the screen is positive. ACOG continues to support both one-step and two-step approaches, noting that the one-step IADPSG protocol identifies more women with GDM but that outcomes data on the population-level benefit of universal one-step screening remain mixed.

The one-step approach (75 g, 2-hour OGTT with IADPSG/WHO cut-offs) is used across most of Europe, Asia, and Australia and consistently yields higher prevalence rates than the two-step approach in the same populations, by an estimated 2-5 percentage points.

First-trimester screening

Some women at very high risk, including those with PCOS, prior GDM, BMI above 30, or a prior stillbirth, may benefit from glucose assessment in the first trimester. Early hyperglycaemia identified before 24 weeks may represent pre-existing undiagnosed type 2 diabetes rather than true GDM, and the distinction matters for management intensity.

What GDM means for women with other conditions WomanRx covers

GDM does not exist in isolation from the other conditions many of our readers manage.

PCOS. As noted above, PCOS approximately triples GDM risk. Women with PCOS managing their condition through cycle monitoring or ovulation induction should be counselled about GDM risk at the start of any pregnancy.

Thyroid disease. Hypothyroidism and GDM share insulin-resistance pathways and often co-occur. A large study in Thyroid found that women with subclinical hypothyroidism in the first trimester had a 60% higher odds of GDM compared with euthyroid women. If you are on levothyroxine and become pregnant, your TSH should be rechecked early, both for thyroid management and as context for GDM risk.

Obesity and metabolic syndrome. Women managing obesity who become pregnant should be counselled that GDM is not inevitable but that pre-pregnancy weight loss reduces risk meaningfully. A 5-10% reduction in pre-pregnancy weight can reduce GDM incidence by roughly 15-20% in observational data.

Eating disorders. Women with a history of binge-eating disorder or bulimia nervosa have elevated rates of gestational weight gain and GDM. Screening for disordered eating patterns in prenatal care is underused and can identify women who need additional nutritional support.

Where the evidence is thin: honest gaps

Women have been under-represented in metabolic research, and GDM epidemiology has specific blind spots you deserve to know about.

Most large prevalence databases rely on hospital delivery records, missing women who deliver outside formal health systems. This systematically undercounts GDM in South Asia, Sub-Saharan Africa, and rural settings globally.

Prevalence data for transgender men carrying pregnancies are essentially non-existent; testosterone exposure before pregnancy may alter insulin sensitivity in ways that change GDM risk, but this has not been formally studied.

Long-term follow-up data after GDM are predominantly from white European-ancestry or East Asian cohorts. Whether the 10-year T2D conversion rates apply equally to Black, Hispanic, Indigenous, or South Asian women in low-resource settings is unclear.

The evidence on whether GLP-1 receptor agonists might prevent GDM in high-risk women, a question increasingly relevant as semaglutide and tirzepatide become widespread, is absent. These drugs are contraindicated in pregnancy and must be stopped before conception, but their pre-conception metabolic benefits for women with PCOS or obesity are biologically plausible and under active study.